Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jgar.2020.07.018 http://scihub22266oqcxt.onion/10.1016/j.jgar.2020.07.018 32763357!7403006!32763357     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Glob+Antimicrob+Resist 2020 ; 22 (ä): 842-844 Nephropedia Template TP {{tp|p=32763357|t=2020. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study |pdf=|usr=}}{{32763357}} gab.com Text Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study JO: J Glob Antimicrob Resist http://www.kidney.de/pget.php?&tw=1&pmid=32763357 #FOAvip AIM: To assess the efficacy and safety of hydroxychloroquine with or without azithromycin) in hospitalized adult patients with COVID-19. METHODS: We utilized a hospital based prospective data registry. The primary end point was to assess the impact of hydroxychloroquine with or without azithromycin, on outcome, length of hospitalization, and time to clinical improvement. We utilized treatment effects with inverse-probability-weighting and Cox proportional hazards models. All analyses accounted for age, gender, race, severity on admission, days from symptoms onset and chronic comorbidities. RESULTS: 36 patients received hydroxychloroquine and were age- and sex-matched to 72 patients with COVID-19 who received supportive care. Compared to supportive care, the use of HCQ did not shorten the time to clinical improvement (+0.23 days; 95% CI: -1.8-2.3 days) nor did it shorten the duration of hospital stay (+0.91 days; 95% CI: -1.1-2.9 days). Additionally, HCQ did not decrease the risk of COVID-19 in-hospital death (aHR 1.67; 95% CI: 0.29-9.36). Finally, we observed a slight QTc prolongation from a baseline of 444 +/- 26 ms to 464 +/- 32 ms (mean+/-SD) among patients receiving hydroxychloroquine with or without azithromycin. CONCLUSION: This study did not yield benefits from hydroxychloroquine use in patients with COVID-19 and monitoring for adverse events is warranted. Nevertheless, the treatment was safely studied under the guidance of an antimicrobial stewardship program. Twit Text FOAVip Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study ????J Glob Antimicrob Resist http://www.kidney.de/pget.php?&tw=1&pmid=32763357 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32763357 #FOAvip English Wikipedia <ref>{{Cite pmid|32763357}}</ref> Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study #MMPMID32763357 Kalligeros M; Shehadeh F; Atalla E; Mylona EK; Aung S; Pandita A; Larkin J; Sanchez M; Touzard-Romo F; Brotherton A; Shah R; Cunha CB; Mylonakis E J Glob Antimicrob Resist 2020[Sep]; 22 (ä): 842-844 PMID32763357show ga AIM: To assess the efficacy and safety of hydroxychloroquine with or without azithromycin) in hospitalized adult patients with COVID-19. METHODS: We utilized a hospital based prospective data registry. The primary end point was to assess the impact of hydroxychloroquine with or without azithromycin, on outcome, length of hospitalization, and time to clinical improvement. We utilized treatment effects with inverse-probability-weighting and Cox proportional hazards models. All analyses accounted for age, gender, race, severity on admission, days from symptoms onset and chronic comorbidities. RESULTS: 36 patients received hydroxychloroquine and were age- and sex-matched to 72 patients with COVID-19 who received supportive care. Compared to supportive care, the use of HCQ did not shorten the time to clinical improvement (+0.23 days; 95% CI: -1.8-2.3 days) nor did it shorten the duration of hospital stay (+0.91 days; 95% CI: -1.1-2.9 days). Additionally, HCQ did not decrease the risk of COVID-19 in-hospital death (aHR 1.67; 95% CI: 0.29-9.36). Finally, we observed a slight QTc prolongation from a baseline of 444 +/- 26 ms to 464 +/- 32 ms (mean+/-SD) among patients receiving hydroxychloroquine with or without azithromycin. CONCLUSION: This study did not yield benefits from hydroxychloroquine use in patients with COVID-19 and monitoring for adverse events is warranted. Nevertheless, the treatment was safely studied under the guidance of an antimicrobial stewardship program. |Adult[MESH] |Aged[MESH] |Antiviral Agents/adverse effects/*therapeutic use[MESH] |Azithromycin/adverse effects/therapeutic use[MESH] |Betacoronavirus/drug effects/isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Comorbidity[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Female[MESH] |Hospitalization[MESH] |Humans[MESH] |Hydroxychloroquine/adverse effects/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH] |Prospective Studies[MESH]Hydroxychloroquine use in hospitalised patients with COVID-19: An obse(epmc).pdf DeepDyve Pubget Overpricing